Lung cancer is the most lethal cancer-related disease worldwide. Since survival rates remain poor, there is an urgent need for more effective therapies that could increase the overall survival of lung cancer patients. Lung tumors exhibit increased levels of oxidative markers with altered levels of antioxidant defenses, and previous studies demonstrated that the overexpression of the antioxidant enzyme catalase (CAT) might control tumor proliferation and aggressiveness. Herein, we evaluated the effect of CAT treatment on the sensitivity of A549 human lung adenocarcinoma cells toward various anticancer treatments, aiming to establish the best drug combination for further therapeutic management of this disease. Exponentially growing A549 cells were treated with CAT alone or in combination with chemotherapeutic drugs (cisplatin, 5-fluorouracil, paclitaxel, daunorubicin, and hydroxyurea). CalcuSyn® software was used to assess CAT/drug interactions (synergism or antagonism). Growth inhibition, NFκB activation status, and redox parameters were also evaluated in CAT-treated A549 cells. CAT treatment caused a cytostatic effect, decreased NFκB activation, and modulated the redox parameters evaluated. CAT treatment exhibited a synergistic effect among most of the anticancer drugs tested, which is significantly correlated with an increased H2O2 production. Moreover, CAT combination caused an antagonism in paclitaxel anticancer effect. These data suggest that combining CAT (or CAT analogs) with traditional chemotherapeutic drugs, especially cisplatin, is a promising therapeutic strategy for the treatment of lung cancer.
Lung cancer A549 cells Catalase Anticancer drug combination Chemotherapy Drug synergism
This is a preview of subscription content, log in to check access.
Brazilians funds MCT/CNPq Universal (470306/2011-4), PRONEX/FAPERGS (1000274), PRONEM/FAPERGS (11/2032-5), PqG/FAPERGS (2414-2551/12-8), MCT/CNPq INCT-TM (573671/2008-7), and FAPERGS/MS/CNPq/SESRS/PPSUS (1121-2551/13-8) provided the financial support without interference in the ongoing work.
Mountzios G, Dimopoulos MA, Soria JC, Sanoudou D, Papadimitriou CA. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Crit Rev Oncol Hematol. 2010;75(2):94–109. doi:10.1016/j.critrevonc.2009.10.002.CrossRefPubMedGoogle Scholar
Visconti R, Grieco D. New insights on oxidative stress in cancer. Curr Opin Drug Discov Dev. 2009;12(2):240–5.Google Scholar
Polytarchou C, Hatziapostolou M, Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J Biol Chem. 2005;280(49):40428–35. doi:10.1074/jbc.M505120200.CrossRefPubMedGoogle Scholar
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMedGoogle Scholar
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.PubMedGoogle Scholar
Dresch MT, Rossato SB, Kappel VD, Biegelmeyer R, Hoff ML, Mayorga P, et al. Optimization and validation of an alternative method to evaluate total reactive antioxidant potential. Anal Biochem. 2009;385(1):107–14. doi:10.1016/j.ab.2008.10.036.CrossRefPubMedGoogle Scholar
Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2007;1(6):3159–65. doi:10.1038/nprot.2006.378.CrossRefGoogle Scholar
Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem. 1997;253(2):162–8. doi:10.1006/abio.1997.2391.CrossRefPubMedGoogle Scholar
Laurent A, Nicco C, Chéreau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948–56.PubMedGoogle Scholar
Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer OL, Costa CS, et al. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog. 2004;39(2):103–13. doi:10.1002/mc.20001.CrossRefPubMedGoogle Scholar
Zanotto-Filho A, Delgado-Canedo A, Schroder R, Becker M, Klamt F, Moreira JC. The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. Cancer Lett. 2010;288(2):192–203. doi:10.1016/j.canlet.2009.06.038.CrossRefPubMedGoogle Scholar
Zanotto-Filho A, Gelain DP, Schroder R, Souza LF, Pasquali MA, Klamt F, et al. The NF kappa B-mediated control of RS and JNK signaling in vitamin A-treated cells: duration of JNK-AP-1 pathway activation may determined cell death or proliferation. Biochem Pharmacol. 2009;77(7):1291–301. doi:10.1016/j.bcp.2008.12.010.CrossRefPubMedGoogle Scholar
Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991;10(8):2247–58.PubMedPubMedCentralGoogle Scholar
Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, Yu JH, et al. Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung Cancer. 2008;60(2):277–84. doi:10.1016/j.lungcan.2007.10.015.CrossRefPubMedGoogle Scholar
Wang D, Xiang DB, Yang X, Chen LS, Li MX, Zhong ZY, et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009;66(3):298–304. doi:10.1016/j.lungcan.2009.02.019.CrossRefPubMedGoogle Scholar
Ma SF, Nishikawa M, Hyoudou K, Takahashi R, Ikemura M, Kobayashi Y, et al. Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. Kidney Int. 2007;72(12):1474–82. doi:10.1038/sj.ki.5002556.CrossRefPubMedGoogle Scholar